Sarepta Therapeutics Inc

NASDAQ: SRPT
$123.46
-$3.67 (-2.9%)
Closing price May 24, 2024

SRPT Chart and Intraday Price

SRPT Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 215 FIRST STREET, SUITE 415, CAMBRIDGE, MA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 12,036.65M USD
Shares Outstanding 93,547,000
Sarepta Therapeutics Inc is a pioneering biopharmaceutical company dedicated to developing unique treatments for rare diseases, with a strong focus on RNA-targeted therapies, gene therapies, and genetic therapeutic modalities. It is known for producing EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, targeting duchenne muscular dystrophy among other conditions. The company is actively working on advancing its pipeline, including SRP-5051 and SRP-9003 for muscular dystrophies. Founded in 1980 and based in Cambridge, Massachusetts, Sarepta collaborates with leading institutions to push the boundaries of genetic medicine.

SRPT Articles

Exxon Mobil and another energy giant saw huge insider buys this week, while Bill Ackman continued to build his stake in Howard Hughes.
Monday's top analyst upgrades and downgrades included Academy Sports and Outdoors, Accenture, Clorox, Fiserv, Moderna, Planet Fitness, Sarepta Therapeutics, Tesla, Under Armour, Ventas, Viatris,...
Tuesday's top analyst upgrades and downgrades included Broadcom, Caterpillar, CVS Health, Guardant Health, Marvell Technology, Nutrien, Paramount Global, RingCentral, SoFi Technologies, UnitedHealth...
Thursday's top analyst upgrades and downgrades included Albertsons Companies, Alphabet, Apple, Coinbase Global, Danaher, Enphase Energy, GE HealthCare Technologies, General Electric, McDonald's,...
Wednesday's top analyst upgrades and downgrades included American Express, Analog Devices, Boeing, Chevron, Chipotle Mexican Grill, Comcast, CSX, Etsy, Fastenal, ONEOK, Prudential Financial, RH and...
Monday's top analyst upgrades and downgrades included Alphabet, Bill, Bumble, Dollar General, FedEx, FMC, Jabil Circuit, Microsoft, Nike, Nvidia, Sarepta Therapeutics, Shopify, Synchrony Financial,...
Friday's top analyst upgrades and downgrades included Advanced Micro Devices, Asana, Etsy, Exact Sciences, Guardant Health, Hilton Worldwide, Meta Platforms, MongoDB, Salesforce, ServiceNow, Sysco...
Thursday's top analyst upgrades and downgrades included AbbVie, AutoZone, Boeing, Coupang, First Solar, Fortinet, Goldman Sachs, Johnson & Johnson, Marqeta, Monster Beverage, Rivian Automotive,...
Friday’s additional top analyst upgrades and downgrades were on Alaska Air, American Airlines, Meta Platforms, New York Times, Southwest Airlines, United Airlines and more.
Monday's top analyst calls were on Activision Blizzard, Amazon.com, Bilibili, Coupa Software, Deere, DraftKings, JD.com, Lufax, Meta Platforms, Redfin, Tyson Foods, Visa, Upstart, Wynn Resorts and...
Barclays recently issued a few calls across multiple industries implying serious upside for each stock, but one in particular with over 30% upside.
Tuesday's top analyst upgrades and downgrades included Analog Devices, Baxter, BorgWarner, Caesars Entertainment, CarMax, Chevron, Hertz Global, Li Auto, Starbucks, Tesla and Twitter.
Here are Tuesday's leaders and laggards in the premarket session. Energy stocks were the day's big winners early on.
Tuesday’s top analyst upgrades and downgrades included Bilibili, Carvana, Crocs, GameStop, Goldman Sachs, Nike, Sarepta Therapeutics, Vir Biotechnology and Weber.
Friday afternoon's analyst upgrades and downgrades included BigCommerce, Citrix, GlaxoSmithKline, Nikola, Regeneron, Shake Shack and more.